Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01696396 · ClinicalTrials.gov registry record · Phase 2
Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 254
- Enrollment target
NCT01696396 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 254 participants.
The verdict
NCT01696396, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 254 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of abrilumab as measured by the proportion of participants achieving Crohn's Disease Activity Index (CDAI) remission (CDAI \< 150) after treatment for 8 weeks.
Interventions
- DRUG Placebo
- DRUG Abrilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2012-12-04 |
| Est. Completion | 2018-04-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01696396
The ClinicalTrials.gov registry entry for NCT01696396 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01696396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01696396 about?
NCT01696396 is a clinical study titled "Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease". The primary objective of this study is to evaluate the efficacy of abrilumab as measured by the proportion of participants achieving Crohn's Disease Activity Index (CDAI) remission (CDAI \< 150) after treatment for 8 weeks.
What is the current status of trial NCT01696396?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2012-12-04. Estimated completion is 2018-04-10.
What interventions are being tested in trial NCT01696396?
The interventions under investigation include: Placebo (DRUG), Abrilumab (DRUG).
Who is sponsoring clinical trial NCT01696396?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.